Based on data collected from different sources by our team,
there are indicators that suggest that this company is no longer active. However, this information may not be accurate.
If you believe this information should be updated, please .
For more details, you can read our .
9/2016 ceased to operate
Metallo-Therapy
Metallo-Therapy Overview
Metallo-Therapy (MT) is developing contrast agents that enable precise tumor detection and monitoring using CT imaging. MT's proprietary gold nanoparticles (GNP) accumulate in malignant tumors and remain therefor a few weeks. Due to their low toxicity and contrasting function, the GNPs can function as nano-markers, supporting and enhancing multiple applications in the management of cancer patients undergoing radiotherapy. Metallo-Therapy is supported by the Chief Scientist of the Israeli Ministry of Economy and by Arkin Holdings, an investment fund focused on innovative technologies in the healthcare market.